Compare HMR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMR | CRDF |
|---|---|---|
| Founded | 1984 | 1999 |
| Country | Greece | United States |
| Employees | 52 | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.3M | 86.8M |
| IPO Year | N/A | 2012 |
| Metric | HMR | CRDF |
|---|---|---|
| Price | $1.11 | $0.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.00 | ★ $9.63 |
| AVG Volume (30 Days) | 64.2K | ★ 1.6M |
| Earning Date | 06-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | $64.04 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $0.73 | $0.76 |
| 52 Week High | $1.71 | $3.31 |
| Indicator | HMR | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 39.21 |
| Support Level | $1.05 | N/A |
| Resistance Level | $1.23 | $2.03 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 51.07 | 81.33 |
Heidmar Maritime Holdings Corp is a commercial and technical management company that operates tanker and dry-bulk vessel pools. The group, along with its subsidiaries, operates as a growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. Its lines of business currently include asset management, tanker pooling, commercial and time charters, assisting clients with the buying and selling of ships, and technical management services for individual vessels, which include assistance in technical operations and crewing of the vessel. Its geographic areas are Singapore, the USA, the Marshall Islands, the United Arab Emirates, Germany, Switzerland, and Other.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.